PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medical Oncology, Gustave Roussy, Villejuif, France.\', \'Drug Development Department, Gustave Roussy, Villejuif, France.\', \'INSERM U1015, Gustave Roussy, Villejuif, France.\', \'Paris Saclay University, Saint-Aubin, France.\', \'Division of Hematology/Oncology, Department of Medicine, University of California, Los Angles, Los Angeles, California.\', \'Drug Development Department, Gustave Roussy, Villejuif, France. Jean-Charles.Soria@gustaveroussy.fr.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1158/2159-8290.CD-21-0144
?:doi
?:hasPublicationType
?:journal
  • Cancer discovery
is ?:pmid of
?:pmid
?:pmid
  • 33846172
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.996
?:rankingScore_hIndex
  • 98
?:title
  • Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33846172>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33846172>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all